Aristo Pharma Nordic ApS: Financial statements 2023
CVR: 32328768
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Aristo Pharma Nordic ApS (CVR 32328768) has filed annual accounts for 2023. In 2023, the company reported a gross profit of EUR 326,645 and a net result of EUR 25,848 compared with EUR 51,525 the year before. That is a decrease of 54.5% compared with the year before. Equity in the 2023 report amounted to EUR 138,095. The solvency ratio was 7.1%. The company had 3 employees in the financial year.
- Gross Profit
- EUR 326,645
- Profit/Loss
- EUR 25,848
- Equity
- EUR 138,095
- Total Assets
- EUR 1,957,421
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 327K EUR | 26K EUR | 138K EUR | 3 |
| 2022 | - | 717K EUR | 52K EUR | 112K EUR | 5 |
| 2021 | - | 789K EUR | 45K EUR | 61K EUR | 7 |
| 2020 | - | 805K EUR | 62K EUR | -1.3M EUR | 7 |
| 2019 | - | 470K EUR | -286K EUR | -1.3M EUR | 6 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Aristo Pharma Nordic ApS has published its annual report for 2022. Gross profit came to DKK 717,126, and the net result was DKK 51,525.
As of January 12, 2023, Robert Maciej Szymanski has joined the board of directors of Aristo Pharma Nordic ApS.
As of January 12, 2023, Kenneth Pedersen has left the board of directors of Aristo Pharma Nordic ApS.
About Aristo Pharma Nordic ApS
Aristo Pharma Nordic ApS is a Danish company of the type Anpartsselskab based in Skovlunde, founded in 2011. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named AMNEAL NORDIC ApS and COPHARMA ApS. The management consists of John Hudson Kriwet. The board consists of John Hudson Kriwet (chair), Jannes Paul Beeskow and Robert Maciej Szymanski. The company is owned by Aristo Pharma GmbH. The company has 1 employee (2026). In 2025, the company reported revenue of EUR 453,392 and a net result of EUR 21,589 compared with EUR 25,190 the year before. Equity in the 2025 report amounted to EUR 184,874.